Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.43 |
| ▸ | HTR3B | O95264 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20303182 | 1.00 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL20302486 | 0.84 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL20302209 | 0.84 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL20302210 | 0.84 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL9901888 | 0.80 | P2RX7 (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL20333652 | 0.80 | GRM4 (0.39) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL21595529 | 0.80 | GRM4 (0.39) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL9901890 | 0.80 | P2RX7 (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL11920132 | 0.77 | HTR3E (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL9926089 | 0.77 | HTR3E (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018118868-A1 | TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2018-06-28 | — | — | WO | disclosed |
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-9403812-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2016-08-02 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-11-12 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322057-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | HTR3E 1972/4885HTR3B 1936/4885HTR3A 1708/4885 |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | HTR3E 1827/4885HTR3B 1840/4885HTR3A 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.